• 1
    Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 10831086.
  • 2
    Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stage Ta and Ti transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995; 153: 18231827.
  • 3
    Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol. 1992; 147: 10201023.
  • 4
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980; 124: 3840.
  • 5
    Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am. 1992; 19: 629639.
  • 6
    Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol. 1994; 73: 533537.
  • 7
    Takahashi R, Hashimoto T, Xu HJ, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci USA. 1991; 88: 52575261.
  • 8
    Serth J, Kuczyk MA, Bokemeyer C, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 1995; 71: 201205.
  • 9
    Llopis J, Alcaraz A, Ribal MJ, et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol. 2000; 37: 644653.
  • 10
    Wolf HK, Stober C, Hohenfellner R, Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in pT1G3 urothelial bladder carcinomas. Tumor Biol. 2001; 22: 328336.
  • 11
    Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study.The Finnbladder group. Eur Urol. 1999; 36: 393400.
  • 12
    Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993; 85: 5359.
  • 13
    Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994; 152(2 pt 1): 388392.
  • 14
    Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol. 2001; 165: 4246.
  • 15
    Cordon-Cardo C, Zhang Z-F, Dalbagni G, et al. Cooperative effects of p53 and RB alterations in primary superficial bladder cancer. Cancer Res. 1997; 57: 12171221.
  • 16
    Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998; 4: 829834.
  • 17
    Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000; 163: 758760.
  • 18
    Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol. 2003; 29: 7480.
  • 19
    Shariat SF, Weizer AZ, Green A, et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000; 56: 735740.
  • 20
    Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney DM. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer. 2004; 91: 552557.
  • 21
    Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003; 61: 11401145.
  • 22
    Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol. 1996; 14: 26462652.
  • 23
    Saint F, Le Frere Belda MA, Quintela R, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG). Eur Urol. 2004; 45: 475482.
  • 24
    Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004; 45: 606612.
  • 25
    Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol. 1997; 157: 16551659.
  • 26
    Lebret T, Becette V, Barbagelatta M, et al. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol. 1998; 159: 788791.
  • 27
    Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol. 1999; 161: 792798. Comment in: J Urol. 1999; 161: 810–811.
  • 28
    Peyromaure M, Weibing S, Sebe P, et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology. 2002; 59: 409413.
  • 29
    Pages F, Flam TA, Vieillefond A, et al. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol. 1998; 159: 10791084.
  • 30
    Wada T, Louhelainen J, Hemminki K, et al. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res. 2000; 6: 610615.
  • 31
    Lipponen PK, Liukkonen TJ. Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol. 1995; 121: 4450.
  • 32
    Lee YS, Teh M. p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer. 1994; 73: 23172323.
  • 33
    Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer. 1994; 74: 15421545.
  • 34
    Teh M, Lee YS. An immunohistochemical study of p53 protein in the different histological subtypes of gastric carcinoma. Pathology. 1994; 26: 432434.
  • 35
    Wee A, Teh M, Raju GC. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol. 1994; 47: 453456.
  • 36
    Wee A, Teh M, Raju GC. p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J Clin Pathol. 1995; 48: 236238.
  • 37
    Raju GC, Teh M, Wee A. An immunohistochemical study of p53 protein in cervical intraepithelial neoplasia and squamous cell carcinoma. Pathology. 1996; 28: 1719.
  • 38
    Teh M, Lee YS. An immunohistochemical study of p53 protein in ovarian mucinous neoplasms. Pathology. 1996; 28: 217219.
  • 39
    Kumar R, Atlas I. Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci U S A. 1992; 89: 65996603.
  • 40
    Ludlow JW, DeCaprio JA, Huang CM, Lee WH, Paucha E, Livingston DM. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell. 1989; 56: 5765.
  • 41
    Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell. 1990; 62: 175185.